Company profile
Nura Bio company profile
Nura Bio is a clinical-stage biopharmaceutical company focused on developing neuroprotective therapies to treat neurological diseases. Nura Bio’s drug candidate, NB-4746, is designed to inhibit the SARM1 protein, which plays a significant role in axon degeneration. This drug has shown promise in preclinical studies for preventing nerve damage and is currently advancing toward phase 1b/2 clinical trials in 2025. The company has raised $140 million in financing to support this and other neuroprotective drug programs.
Business identity
- Website
- https://nurabio.com
- Contact email
- [email protected]
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 11-50 employees
- Revenue range
- $0-$1M
- Founded
- 2018-01-01, Year
Headquarters
- Headquarters
- South San Francisco, California, United States
- Country code
- US
- Continent
- North America